Showing results (31-40 of 61) with videos related to
Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanomaKarl D Lewis, William A Robinson, Martin McCarter, et al.Journal for Immunotherapy of Cancer|May 10, 2020
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory responseFernanda I Arnaldez, Steven J O'Day, Charles G Drake, et al.Journal for Immunotherapy of Cancer|August 18, 2016
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanomaAsim Amin, David H Lawson, April K S Salama, et al.Annals of the New York Academy of Sciences|June 19, 2013
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanomaJedd D Wolchok, F Stephen Hodi, Jeffrey S Weber, et al.Frontiers in Oncology|June 7, 2014
Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 LevelsAnna M Leung, Agnes Fermin Lee, Junko Ozao-Choy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapyTakuji Mori, Steven J O'Day, Naoyuki Umetani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanomaSanjiv S Agarwala, John Glaspy, Steven J O'Day, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanomaKevin B Kim, Jeffrey A Sosman, John P Fruehauf, et al.The Lancet. Oncology|December 17, 2009
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyJedd D Wolchok, Bart Neyns, Gerald Linette, et al.Annals of Surgery|October 9, 2002
Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodesDonald L Morton, Eddy C Hsueh, Richard Essner, et al.Pageof 7